Our friends at UroToday have just posted another four video interviews from the Advanced Prostate Cancer Consensus Conference at St. Gallen in Switzerland, some of which are likely to be of interest to some of our readers. They include:
- Alicia Morgans’ interview of Drs Philip Kantoff and Lorelei Mucci on outcomes research and the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) project
- Neal Shore’s interview of Dr. Kantoff related to testing for the AR-V7 mutation and how the results of such testing can affect decisions about treatment with specific drug therapies
- Alicia Morgans’ interview of Dr. Susan Halabi about the appropriate use of subgroup analysis of data from clinical trials and how clinicians (and patients) need to think about this and related issues
- Charles Ryan’s discussion with Dr. Ian Tannock about using older, cheaper drugs in the treatment of prostate cancer — particularly in those parts of the world where the costs associated with treatment of prostate cancer can be prohibitive with regard to the use of newer types of therapy
Filed under: Uncategorized | Tagged: conference, interviews, St. Gallen, video |
Sitemaster,
You have enthusiastically given your support for the Metastatic Prostate Cancer Project at the Broad Institute, and I am participating. Are you similarly in support of the Ironman Registry and would you also encourage eligible men to participate in that study? Thank you.
Richard
Dear Richard:
I have no detailed knowledge about the Ironman Registry. It doesn’t seem to have a patient advisory board. And it isn’t collecting genetic data.
On the other hand, it clearly has a lot of smart clinicians involved.
I am supportive of all good, large, well-organized registry studies that can potentially develop data that may help us to better understand the evolution and management of prostate cancer. However, it truth I can’t understand why there are two different studies like this being done. Why wouldn’t they just be combined together?
:O)